Personalized ustekinumab for perianal fistulizing Crohn's disease
Part of Digestive system clinical trials.
This study tailors ustekinumab (Stelara) treatment specifically for people with fistulizing Crohn's disease around the anus. It aims to find the best way to use this medicine to improve symptoms like pain and drainage from fistulas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have perianal fistulizing Crohn's disease (fistulas around the anus due to Crohn's).
- You must be currently receiving treatment with ustekinumab (Stelara).
- You cannot be taking steroids, immunosuppressants, other biologics, or small molecule drugs at the same time.
- You must not have another autoimmune disease (like lupus or rheumatoid arthritis).
- You must not have a serious active infection (like active tuberculosis, EBV, or cytomegalovirus).
- You must not have any active cancer or a history of malignant tumor.
- Your medical records must be complete (less than 30% missing data) and you must agree to follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests ustekinumab, a medicine that calms immune inflammation, to see if it can improve symptoms in people with Crohn’s disease that causes bowel narrowing. It may help if your Crohn’s symptoms come from strictures (narrowed areas) seen on scans or endoscopy.
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
This study tests a new treatment for people with Crohn's disease who have lost response to ustekinumab (Stelara). It aims to see if a different dosing or additional treatment can help regain control of symptoms.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
This study tests whether adjusting the dose of infliximab (a biologic medicine given by IV) based on drug levels in your blood works better for treating draining fistulas caused by Crohn's disease. It is for people who have not tried other biologics and whose fistulas have not healed with usual treatments.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.